MicroRNA 302b-3p/302c-3p/302d-3p inhibits epithelial&amp;ndash;mesenchymal  transition and promotes apoptosis in human endometrial carcinoma cells

Li, Yibing; Huo, Jianing; Pan, Xin; Wang, Cuicui; Ma, Xiaolong

doi:10.2147/ott.s154517

Cited by 27 publications

(20 citation statements)

References 26 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that miR-302s inhibits CDK4 and CCND1 expression and regulates cell cycle [15,16]. Moreover, the miR-302s decreased cancer cell proliferation by down-regulating the SDC1, SOX1 and SHH [17]. Thus, miR-302s showed tumor suppressive activity in a number of solid tumors.…”

Section: Discussionmentioning

confidence: 94%

LncRNA SNHG16 promotes cell proliferation through miR-302a-3p/FGF19 axis in hepatocellular carcinoma

Song

et al. 2019

neo

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide and the leading cause of death in Asian and African countries. Aberrant accumulation of lncRNAs is one of the major causes of tumorigenesis in HCC. Small nucleolar RNA host gene 16 (SNHG16) is identified as an oncogene in multiple types of tumors. However, the role of SNHG16 in HCC is poorly understood. Herein, we show that SNHG16 is up-regulated and associated with poor prognosis in HCC. We also demonstrate that SNHG16 interacts with miR-302a-3p and decreases its expression. Moreover, our results indicate that SNHG16/miR-302a-3p axis regulates expression of the FGF19 in liver cancer cells. Finally, we investigated the biological function of SNHG16 in HCC and showed that SNHG16 promotes liver cancer cell proliferation via the SNHG16/ miR-302a-3p/FGF19 axis. Collectively, these data suggest that SNHG16 might be a predictive biomarker and a potential therapeutic target in liver cancer.

show abstract

Section: Discussionmentioning

confidence: 94%

LncRNA SNHG16 promotes cell proliferation through miR-302a-3p/FGF19 axis in hepatocellular carcinoma

Song

et al. 2019

neo

View full text Add to dashboard Cite

show abstract

“…One study of malignant pleural mesothelioma indicated that miR‐302b can inhibit tumor cell tumorsphere growth by targeting Mcl‐1 to inhibit proliferation and induce apoptosis . Additionally, in HECCs, miR‐302b/c/d was confirmed to promote apoptosis by downregulating zinc‐finger E‐box binding homeobox 1 and Bcl‐2 and upregulating BAX …”

Section: Functions and Mechanisms Of Mir‐302 Cluster In Tumor Developmentioning

confidence: 94%

Application of the microRNA‐302/367 cluster in cancer therapy

Liu

Wang

et al. 2020

Cancer Science

View full text Add to dashboard Cite

This is an open access article under the terms of the Creat ive Commo ns Attri butio n-NonCo mmerc ial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. , glycogen synthase kinase-3β; HCC, hepatocellular carcinoma; HECC, human endometrial carcinoma cell; hESC, human embryonic stem cell; IGF-1R, insulin-like growth factor 1 receptor; iPSCs, induced pluripotent stem cells; JNK, c-Jun NH2-terminal kinase; KLF4, Kruppel Like Factor 4; KPNA2, NF-κB-inducing kinase and karyopherin α2; LATS2, large tumor suppressor kinase 2; lncRNA, long noncoding RNA; LSCC, laryngeal squamous cell carcinoma; Mcl-1, myeloid cell leukemia sequence 1; MIAT, myocardial infarction-associated transcript; miRNA, microRNA; mirPS, miRNA-induced pluripotent stem; MTDH, metadherin; ncRNA, noncoding RNA; NK, natural killer; Notch4, notch receptor 4; NR2F2, nuclear receptor subfamily 2 group F member 2; OC, ovarian cancer; OCT, organic cation/carnitine transporter; PCa, prostate cancer; P-gp, P-glycoprotein; PRP-1, proline-rich polypeptide 1; RACK1, receptor for activated C-kinase 1; S1pr1, sphingosine-1-phosphate receptor 1; SDC1, syndecan 1; SDF1, stromal cell-derived factor 1; SHH, sonic hedgehog; SOX2, SRY-box transcription factor 2; Tcf3, transcription factor 3; SSEA-4, stage-specific embryonic antigen-4; YAP, Yes-associated transcriptional regulator. AbstractAs a novel class of noncoding RNAs, microRNAs (miRNAs) can effectively silence their target genes at the posttranscriptional level. Various biological processes, such as cell proliferation, differentiation, and motility, are regulated by miRNAs. In different diseases and different stages of disease, miRNAs have various expression patterns, which makes them candidate prognostic markers and therapeutic targets.Abnormal miRNA expression has been detected in numerous neoplastic diseases in humans, which indicates the potential role of miRNAs in tumorigenesis. Previous studies have indicated that miRNAs are involved in nearly the entire process of tumor development. MicroRNA-302a, miR-302b, miR-302c, miR-302d, and miR-367 are members of the miR-302/367 cluster that plays various biological roles in diverse neoplastic diseases by targeting different genes. These miRNAs have been implicated in several unique characteristics of cancer, including the evasion of growth suppressors, the sustained activation of proliferative signaling, the evasion of cell death and senescence, and the regulation of angiogenesis, invasion, and metastasis.This review provides a critical overview of miR-302/367 cluster dysregulation and the subsequent effects in cancer and highlights the vast potential of members of this cluster as therapeutic targets and novel biomarkers. K E Y W O R D Sbiological phenomena, cell dedifferentiation, MIRN302, neoplasm, therapy

show abstract

“…Wound healing assay were performed according our previously described [29]. Cells were observed by microscopy and photographed (0 h and 24 h cell scratches).…”

Section: Wound Healing Assaymentioning

confidence: 99%

BTG1 inhibits malignancy as a novel prognosis signature in endometrial carcinoma

Huo

et al. 2020

Cancer Cell Int

Self Cite

View full text Add to dashboard Cite

Background Endometrial carcinoma (EC) is one of the three major malignant tumors of the female reproductive system. In recent years, the incidence and mortality rate of EC have increased. B-cell translocation gene 1 (BTG1) is an anti-proliferation gene that regulates the occurrence and development of a variety of tumors, but there is no research regarding this gene in EC. Methods Based on The Cancer Genome Atlas (TCGA) database, we used a variety of bioinformatics tools and databases to explore the expression and prognosis of BTG1. We verified expression and prognosis of BTG1 in EC using qRT-PCR and analyzed the relevant clinicopathological parameters. We functionally enriched BTG1 and related genes in EC patients through the bioinformatics website and analyzed miRNA targets of BTG1 and interacting protein networks. Cell proliferation, wound healing, transwell invasion, and cell apoptosis assays were used to detect the effects of BTG1 on the malignant biological behavior of endometrial carcinoma cells (ECCs). The effect of BTG1 on the epithelial-to-mesenchymal transition (EMT) process was detected using western blot. Results We analyzed the expression and prognosis of BTG1 based on TCGA and found that low expression of BTG1 was associated with poor EC prognosis. The qRT-PCR suggested that BTG1 had low expression in EC. BTG1 expression was significantly correlated with overall survival (OS) shortening. Clinicopathological analysis suggested that expression of BTG1 was related to invasion depth and the International Federation of Gynecology and Obstetrics (FIGO) stage. EC pathological tissue type, fertility history, lymphatic metastasis, menopause, estrogen receptor (ER), progesterone receptor (PR), and age of diagnosis were not related. Functional enrichment analysis showed that BTG1 plays an important role in regulating embryonic development, tumorigenesis, apoptosis, and cell cycle. Biological behavior experiments suggest that BTG1 inhibits proliferation, migration, and invasion of ECCs, and promotes apoptosis of ECCs. Western blot indicated that BTG1 inhibited the EMT process of ECCs. Conclusions BTG1, as a tumor suppressor gene, plays an important role in the occurrence and development of EC. We believe that BTG1 can be used as a potential prognostic biomarker for EC.

show abstract

MicroRNA 302b-3p/302c-3p/302d-3p inhibits epithelial–mesenchymal transition and promotes apoptosis in human endometrial carcinoma cells

Cited by 27 publications

References 26 publications

LncRNA SNHG16 promotes cell proliferation through miR-302a-3p/FGF19 axis in hepatocellular carcinoma

LncRNA SNHG16 promotes cell proliferation through miR-302a-3p/FGF19 axis in hepatocellular carcinoma

Application of the microRNA‐302/367 cluster in cancer therapy

BTG1 inhibits malignancy as a novel prognosis signature in endometrial carcinoma

Contact Info

Product

Resources

About